A2 Biotherapeutics Advances A2B395 in Solid Tumors
AGOURA HILLS, Calif. — September 15, 2026 A2 Biotherapeutics announced encouraging early safety and efficacy findings from the ongoing...
Cell Therapy
Advertisement
Mission Bio Launches Tapestri Triomics for Single-Cell Analysis
SOUTH SAN FRANCISCO, Calif. — September 16, 2026 Mission Bio announced the launch of Tapestri® Triomics, a new expansion...
AbelZeta’s C-CAR168 Receives FDA IND Clearance
San Diego, California, U.S., September 14, 2026 AbelZeta Therapeutics has announced that the U.S. Food and Drug Administration (FDA)...
Resolution Therapeutics Completes RTX001 EMERALD Enrollment
EDINBURGH and LONDON, UK — September 11, 2026 Resolution Therapeutics Limited announced that the final patient has been treated...
Fate Therapeutics Presents FT819 Clinical Data at CCR-West 2026
SAN DIEGO — September 9, 2026 Fate Therapeutics, Inc. announced that new clinical data for its off-the-shelf anti-CD19 CAR...
Advertisements
BrainChild Bio Initiates Pivotal Phase 2 Trial of BCB-276 for DIPG
SEATTLE, Washington and CAMBRIDGE, Massachusetts — September 8, 2026 BrainChild Bio, Inc. announced the initiation of the pivotal Phase...
Sernova and Seraxis Merge to Create BetaNova Biotherapeutics
TORONTO, Canada and GERMANTOWN, Maryland — September 8, 2026 Sernova Biotherapeutics Inc. and Seraxis Holdings, Inc. announced a definitive...
Nkarta to Present Initial NKX019 Autoimmune Data at ACR 2026
SOUTH SAN FRANCISCO, California — September 8, 2026 Nkarta, Inc. announced that three scientific presentations featuring NKX019 have been...
Artiva Biotherapeutics Advances AlloNK Toward Phase 3 in RA
SAN DIEGO, California — September 8, 2026 Artiva Biotherapeutics, Inc. announced planned clinical data disclosures and development milestones for...
BMS Reports Positive Phase 2 CAR T Cell Trial Results
Princeton, New Jersey, U.S., September 8, 2026 Bristol Myers Squibb (BMS) has announced positive topline results from the registrational...
Advertisement
